Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY18.85 CNY
Change Today +0.33 / 1.78%
Volume 38.8M
300039 On Other Exchanges
Symbol
Exchange
Shenzhen
As of 3:00 AM 05/25/15 All times are local (Market data is delayed by at least 15 minutes).

shanghai kaibao pharmaceut-a (300039) Snapshot

Open
CNY18.20
Previous Close
CNY18.52
Day High
CNY18.93
Day Low
CNY18.17
52 Week High
05/19/15 - CNY20.25
52 Week Low
05/29/14 - CNY8.95
Market Cap
15.7B
Average Volume 10 Days
41.3M
EPS TTM
CNY0.43
Shares Outstanding
832.5M
EX-Date
04/30/15
P/E TM
43.4x
Dividend
CNY0.15
Dividend Yield
0.82%
Current Stock Chart for SHANGHAI KAIBAO PHARMACEUT-A (300039)

Related News

No related news articles were found.

shanghai kaibao pharmaceut-a (300039) Related Businessweek News

No Related Businessweek News Found

shanghai kaibao pharmaceut-a (300039) Details

Shanghai Kaibao Pharmaceutical Co., Ltd. researches, develops, manufactures, and distributes Chinese medicines in China. The company offers clear away heat and toxic material injections, which are applied in the treatment of upper respiratory tract infections, such as cold and pneumonia; and doxofylline capsules for the treatment of bronchial asthma, chronic asthmatic bronchitis, and other breathing difficulties that are caused by bronchial spasms. It also provides pioglitazone hydrochloride tablets for the treatment of type 2 diabetes; captopril sustained-release tablets for treating high blood pressure and heart failure; and other drugs. Shanghai Kaibao Pharmaceutical Co., Ltd. was founded in 2000 and is based in Shanghai, China.

Founded in 2000

shanghai kaibao pharmaceut-a (300039) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

shanghai kaibao pharmaceut-a (300039) Key Developments

Shanghai Kaibao Pharmaceutical Co., Ltd.(SZSE:300039) added to Shenzhen Stock Exchange Component A Share Index

Shanghai Kaibao Pharmaceutical Co., Ltd. has been added to Shenzhen Stock Exchange Component A Share Index.

Shanghai Kaibao Pharmaceutical Co., Ltd.(SZSE:300039) added to Shenzhen Stock Exchange Component Index

Shanghai Kaibao Pharmaceutical Co., Ltd. has been added to Shenzhen Stock Exchange Component Index.

Shanghai Kaibao Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2014; Approves Amendments to the Articles of Association

Shanghai Kaibao Pharmaceutical Co., Ltd. announced that at the AGM held on April 17, 2015, the shareholders approved the cash dividend of CNY 2.00000000 (taxes included) per 10 shares for the Year 2014. The company also approved the amendments to the articles of association of the company, at its AGM.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
300039:CH CNY18.85 CNY +0.33

300039 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 300039.
View Industry Companies
 

Industry Analysis

300039

Industry Average

Valuation 300039 Industry Range
Price/Earnings 42.5x
Price/Sales 10.1x
Price/Book 7.8x
Price/Cash Flow 43.0x
TEV/Sales 9.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHANGHAI KAIBAO PHARMACEUT-A, please visit www.xykb.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.